674782-26-4
674782-26-4 structure
- Name: Leronlimab
- Chemical Name: Leronlimab
- CAS Number: 674782-26-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Anti-infection HIV
- Create Date: 2023-04-04 14:33:32
- Modify Date: 2024-09-04 11:40:12
-
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1].
| Name | Leronlimab |
|---|
| Description | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Leronlimab (1-140 mg/mL) 结合 CCR5 阳性细胞高达 98%[1]。 Leronlimab (80-1750 μg/mL) 阻断 MDA-MB-231 细胞中 CCL5，CCL3 和 CCL4 诱导的钙反应[1]。 Leronlimab (175 和 350 mg/mL) 阻断 MDA-MB-231 细胞侵袭[1]。 Leronlimab (10 μg/mL；72 小时) 增强 doxorubicin 对 MDA-MB-231 细胞的细胞毒性[1]。 Cell Cytotoxicity Assay[1] Cell Line: MDA-MB-231 cell line Concentration: 10 μg/mL Incubation Time: 72 hours Result: Increased the cells killing effect induced by doxorubicin. |
| In Vivo | Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况[1]。 Animal Model: Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection[1] Dosage: 2 mg Administration: Intraperitoneal injection; 2 mg, twice a week Result: Reduced the volume of pulmonary metastases at 8 weeks. |
| References |
| Storage condition | 2-8°C |
|---|